ERBB2 and breast cancer: The likelihood of distant recurrence and cancer-specific death in triple-negative [ER(−), PR(−) and HER2(−)] breast cancer is larger than that of non-triple-negative cases, and the maximum difference is observed at 3 years after diagnosis.